换一批
换一批摘要肺纤维化是严重危害人类健康的公共卫生问题,诊断后中位生存期仅为2～3年,目前已有的抗肺纤维化药物疗效甚微.随着肺纤维化发病机制的进展,多种潜在的抗肺纤维化药物靶点被发现.本文概述肺纤维化的流行病学情况、病因和发病机制,重点介绍作用于炎症、氧化应激、肺泡上皮细胞、肌成纤维细胞等靶点的抗肺纤维化药物的开发现状及展望.
更多相关知识
abstractsPulmonary fibrosis is a serious public problem threatening people's health with a median survival time of 2 3 years after diagnosis.Currently,anti-fibrotic drugs have showed little effect.With the advances of mechanisms of pulmonary fibrosis,multiple potential anti-fibrotic targets have been developed.This review summarizes the epidemiology,etiology and pathogenesis of pulmonary fibrosis,and then emphasizes on the prospects of new anti-fibrotic drugs that mainly target inflammation,oxidative stress,alveolar epithelial cells and myofibroblasts.
More相关知识
主题词
肺纤维化(Pulmonary Fibrosis)药用制剂(Pharmaceutical Preparations)研究(Research)临床试验(Clinical Trial)人类(Humans)
栏目名称
综述
DOI
10.3760/cma.j.issn.1673-436X.2017.18.017
发布时间
2017-11-07
基金项目
国家自然科学基金项目(81470255).National Natural Science Foundation of China
- 浏览281
- 被引3
- 下载197
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
